Metabolic

What Is Tesamorelin?

Tesamorelin is a stabilized GHRH analog used in laboratory models of growth-hormone-axis and metabolic signaling.

Disclaimer: Information is for research and educational purposes only. Catalog materials are not approved for human or veterinary use.

Tesamorelin is a synthetic analog of growth hormone–releasing hormone (GHRH). In endocrine research it is used to study upstream activation of the growth-hormone axis rather than supplying growth hormone as the reagent. Zeptix Labs lists tesamorelin as a research-use-only peptide.

Research material is not a pharmacy product

A tesamorelin-containing prescription product exists in a specific FDA-approved indication. That approved drug is not what a research catalog sells. Research-grade tesamorelin from Zeptix Labs is a laboratory material. It is not a substitute for a prescription, and it is not for human or veterinary use.

Why labs order a GHRH analog

  • GHRH-receptor and pituitary-signaling models.
  • Downstream IGF-1 pathway readouts in experimental systems.
  • Metabolic-marker and adipose-signaling research contexts.

Nearby catalog items

Ipamorelin and the CJC-1295 no DAC + Ipamorelin blend sit in a related hormone-axis theme but act through different receptors. MOTS-c and the GLP series are metabolic-theme neighbors with different mechanisms. Pick the SKU that matches the pathway under test.

Tesamorelin from Zeptix Labs is for qualified laboratory research only. Not for diagnosis, treatment, supplementation, or compounding.

Research context and evidence base

Tesamorelin literature includes receptor pharmacology and studies of a regulated prescription formulation. A research-grade vial is not that approved drug product. Investigators should distinguish GHRH-receptor activity, downstream endocrine markers, formulation, population, and regulatory context before deciding whether a paper informs a laboratory question.12

How to interpret the published evidence

Evidence should be sorted by study type before it is summarized. Analytical characterization establishes what material was tested; cell work can suggest pathways; animal models can explore integrated biology; and human studies, when they exist, apply only to their regulated product, population, and design. One layer should not be presented as if it proves the next.3

Experimental design questions

Tesamorelin studies should distinguish receptor-level activity from downstream GH or IGF-1 measurements and from body-composition endpoints used in regulated clinical trials. An intact pituitary axis, formulation, sampling schedule, and comparator all affect interpretation. Research material should not be evaluated by copying a prescription-product administration schedule.

Building a reproducible laboratory record

For work involving What Is Tesamorelin, record the supplier, SKU, lot number, labeled amount, receipt date, storage history, reconstitution conditions, concentration calculation, control material, instrument or assay version, and prespecified endpoint. Keep the matching certificate of analysis with the run record. These details make a result auditable and help distinguish biological variation from a handling or identity problem.

  • Match the exact compound, sequence, modification, and formulation to the cited methods.
  • Use positive, negative, and vehicle controls appropriate to the assay.
  • Define concentrations, time points, exclusions, and endpoints before reviewing results.
  • Report null and unexpected findings alongside the planned readouts.

Quality, limitations, and research-use status

A certificate of analysis supports lot traceability but does not establish a biological outcome. Investigators remain responsible for method suitability, independent confirmation when required, and compliance with institutional rules. Zeptix Labs materials are supplied for qualified laboratory research only and are not drugs, supplements, cosmetics, foods, or materials for human or veterinary administration.

Reporting results without overreach

When reporting What Is Tesamorelin, state what the experiment directly measured and keep interpretation within that boundary. Include model limitations, uncertainty, failed quality controls, and alternative explanations. Avoid turning preclinical observations into treatment language or assuming that a statistically significant marker change is biologically important. Clear limitations make the article more useful to researchers and prevent laboratory evidence from being mistaken for consumer guidance.

References

  1. Falutz, J., et al. “Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV.” New England Journal of Medicine 357, no. 23 (2007): 2359–70. https://pubmed.ncbi.nlm.nih.gov/18057338/
  2. Falutz, J., et al. “Effects of Tesamorelin, a Growth Hormone–Releasing Factor, in HIV-Infected Patients with Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial with a Safety Extension.” Journal of Acquired Immune Deficiency Syndromes 53, no. 3 (2010): 311–22. https://pubmed.ncbi.nlm.nih.gov/20101189/
  3. Spooner, L. M., and Olin, J. L. “Tesamorelin: A Growth Hormone–Releasing Factor Analogue for HIV-Associated Lipodystrophy.” Annals of Pharmacotherapy 46, no. 2 (2012): 240–47. https://pubmed.ncbi.nlm.nih.gov/22274143/
  4. U.S. National Library of Medicine. EGRIFTA WR (tesamorelin) Prescribing Information. DailyMed. Revised March 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75
  5. González-Sales M, Barrière O, Tremblay PO, Nekka F, Desrochers J. Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. Clinical Pharmacokinetics. 2015;54(3):303–313. https://pubmed.ncbi.nlm.nih.gov/25358450/
  6. González-Sales M, Barrière O, Tremblay PO, Nekka F, Desrochers J. Population pharmacokinetic and pharmacodynamic analysis of tesamorelin and its effects on growth hormone and insulin-like growth factor 1. Journal of Pharmacokinetics and Pharmacodynamics. 2015;42(3):287–299. PMID: 25895899. 2015. https://pubmed.ncbi.nlm.nih.gov/25895899/
  7. Zhou F, Zhang H, Cong Z, et al. Structural basis for activation of the growth hormone-releasing hormone receptor. Nature Communications. 2020;11(1):5205. https://pubmed.ncbi.nlm.nih.gov/33060564/
  8. Rivier J, Spiess J, Thorner MO, Vale W. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature. 1982;300(5889):276–278. https://pubmed.ncbi.nlm.nih.gov/6292724/
  9. Guillemin R, Brazeau P, Bohlen P, et al. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 1982;218(4572):585–587. https://pubmed.ncbi.nlm.nih.gov/6812220/
  10. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin in HIV-infected patients with excess abdominal fat: pooled analysis of two multicenter, double-blind, placebo-controlled Phase 3 trials with safety-extension data. Journal of Clinical Endocrinology & Metabolism. 2010;95(9):4291–4304. https://pubmed.ncbi.nlm.nih.gov/20554713/
Catalog

Related products

Continue reading

Related articles